Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy-Reference-Cited by-同舟云学术

Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy

Published:2018-09 Issue: Volume:78 Page:236-246
ISSN:1742-7061
Container-title:Acta Biomaterialia
language:en
Short-container-title:Acta Biomaterialia

Author:

Merckx Pieterjan,De Backer Lynn,Van Hoecke Lien,Guagliardo Roberta,Echaide Mercedes,Baatsen Pieter,Olmeda Bárbara,Saelens Xavier,Pérez-Gil Jésus,De Smedt Stefaan C.,Raemdonck Koen

Funder

Spanish Ministry of Economy

FWO

Ghent University

IWT

Publisher

Elsevier BV

Subject

Molecular Biology,Biomedical Engineering,Biochemistry,Biomaterials,General Medicine,Biotechnology

Reference38 articles.

1. WHO-The top 10 causes of death. http://www.who.int (accessed 10.07. 2015).

2. Current prospects for RNA interference-based therapies;Davidson;Nat. Rev. Genet.,2011

3. Knocking down disease: a progress report on siRNA therapeutics;Wittrup;Nat. Rev. Genet.,2015

4. Delivery of RNAi therapeutics to the airways-from bench to bedside;Qiu;Molecules,2016

5. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy;De Backer;J. Controlled Release,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanogels: smart tools to enlarge the therapeutic window of gene therapy;International Journal of Pharmaceutics;2024-02

2. Intratracheal administration of programmable DNA nanostructures combats acute lung injury by targeting microRNA-155;International Journal of Pharmaceutics;2024-02

3. The alpha-adrenergic antagonist prazosin promotes cytosolic siRNA delivery from lysosomal compartments;Journal of Controlled Release;2023-12

4. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano–bio interactions;Advanced Drug Delivery Reviews;2023-12

5. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy;Advanced Drug Delivery Reviews;2023-11